OTCMKTS:TRLPF - Acerus Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2828 -0.06 (-17.93 %)
(As of 05/23/2018 05:16 AM ET)
Previous Close$0.3446
Today's Range$0.2828 - $0.2973
52-Week Range$0.0750 - $0.4036
Volume4,700 shs
Average Volume11,170 shs
Market Capitalization$59.99 million
P/E RatioN/A
Dividend YieldN/A

About Acerus Pharmaceuticals (OTCMKTS:TRLPF)

Acerus Pharmaceuticals logoAcerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive TRLPF News and Ratings via Email

Sign-up to receive the latest news and ratings for TRLPF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.60
Current Ratio1.52
Quick Ratio0.97


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.44 million
Price / Sales9.36
Cash FlowN/A
Price / CashN/A
Book Value$0.03 per share
Price / Book9.43


EPS (Most Recent Fiscal Year)N/A
Net Income$-8,710,000.00
Net Margins-153.18%
Return on Equity-132.81%
Return on Assets-49.06%


Outstanding Shares213,190,000

Acerus Pharmaceuticals (OTCMKTS:TRLPF) Frequently Asked Questions

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TRLPF."

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals (OTCMKTS:TRLPF) released its quarterly earnings data on Tuesday, March, 20th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter. The specialty pharmaceutical company earned $2.10 million during the quarter. Acerus Pharmaceuticals had a negative return on equity of 132.81% and a negative net margin of 153.18%. View Acerus Pharmaceuticals' Earnings History.

When is Acerus Pharmaceuticals' next earnings date?

Acerus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, August, 10th 2018. View Earnings Estimates for Acerus Pharmaceuticals.

Who are some of Acerus Pharmaceuticals' key competitors?

Who are Acerus Pharmaceuticals' key executives?

Acerus Pharmaceuticals' management team includes the folowing people:
  • Mr. Luc Mainville, Interim CEO & Director (Age 54)
  • Ms. Tricia Symmes, Chief Operating Officer
  • Dr. Nathan Bryson B.Sc Chemistry, Ph.D., VP of Scientific Affairs
  • Mr. Ken Yoon, Chief Financial Officer
  • Mr. Philippe Savard, VP of Legal Affairs & Corp. Sec.

Has Acerus Pharmaceuticals been receiving favorable news coverage?

News stories about TRLPF stock have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acerus Pharmaceuticals earned a daily sentiment score of 0.15 on Accern's scale. They also gave headlines about the specialty pharmaceutical company an impact score of 46.02 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Acerus Pharmaceuticals?

Shares of TRLPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acerus Pharmaceuticals' stock price today?

One share of TRLPF stock can currently be purchased for approximately $0.2828.

How big of a company is Acerus Pharmaceuticals?

Acerus Pharmaceuticals has a market capitalization of $59.99 million and generates $6.44 million in revenue each year. Acerus Pharmaceuticals employs 17 workers across the globe.

How can I contact Acerus Pharmaceuticals?

Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The specialty pharmaceutical company can be reached via phone at 416-679-0771 or via email at [email protected]

MarketBeat Community Rating for Acerus Pharmaceuticals (TRLPF)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuticals and other stocks. Vote "Outperform" if you believe TRLPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRLPF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acerus Pharmaceuticals (OTCMKTS:TRLPF) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ABuyBuy
Consensus Rating Score: N/AN/A3.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Acerus Pharmaceuticals (OTCMKTS:TRLPF) Consensus Price Target History

Price Target History for Acerus Pharmaceuticals (OTCMKTS:TRLPF)

Acerus Pharmaceuticals (OTCMKTS:TRLPF) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
3/22/2017Roth CapitalReiterated RatingBuyView Rating Details
(Data available from 5/23/2016 forward)


Acerus Pharmaceuticals (OTCMKTS:TRLPF) Earnings History and Estimates Chart

Earnings by Quarter for Acerus Pharmaceuticals (OTCMKTS:TRLPF)

Acerus Pharmaceuticals (OTCMKTS TRLPF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/20/2018Q4 2017($0.01)$2.10 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.01)$1.90 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.01)($0.01)$1.72 million$1.45 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.01)($0.01)$1.70 million$1.27 millionViewN/AView Earnings Details
8/8/2016Q2 2016$0.03$2.14 millionViewN/AView Earnings Details
5/4/2016Q1 2016($0.01)$0.03$2.05 million$10.41 millionViewN/AView Earnings Details
3/2/2016Q4 2015($0.01)$0.01$3.01 million$8.15 millionViewN/AView Earnings Details
11/4/2015Q3 2015($0.02)$0.01$3.05 million$2.82 millionViewN/AView Earnings Details
8/5/2015($0.01)($0.01)$2.52 million$2.74 millionViewN/AView Earnings Details
3/18/2015($0.02)($0.04)ViewN/AView Earnings Details
3/5/2015Q4 2014($0.02)($0.04)$2.20 million$2.57 millionViewN/AView Earnings Details
11/7/2014($0.02)($0.02)$1.75 million$1.75 millionViewN/AView Earnings Details
7/30/2014Q2 2014($0.05)ViewN/AView Earnings Details
6/17/2014($0.04)($0.02)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.04)($0.02)ViewN/AView Earnings Details
3/5/2014Q4 2013($0.04)($0.07)ViewN/AView Earnings Details
11/4/2013Q3 2013($0.04)($0.03)ViewN/AView Earnings Details
7/31/2013Q2 2013($0.04)($0.07)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.04)($0.09)ViewN/AView Earnings Details
3/25/2013Q4 2012($0.04)($0.09)ViewN/AView Earnings Details
11/8/2012Q3 2012($0.04)($0.07)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.04)($0.09)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.04)($0.08)ViewN/AView Earnings Details
3/9/2012Q4 2011($0.04)($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Acerus Pharmaceuticals (OTCMKTS:TRLPF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Acerus Pharmaceuticals (OTCMKTS TRLPF) Insider Trading and Institutional Ownership History

Insider Trading History for Acerus Pharmaceuticals (OTCMKTS:TRLPF)

Acerus Pharmaceuticals (OTCMKTS TRLPF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)


Acerus Pharmaceuticals (OTCMKTS TRLPF) News Headlines

Acerus Pharmaceuticals (TRLPF) CEO Edward Gudaitis on Q1 2018 Results - Earnings Call TranscriptAcerus Pharmaceuticals' (TRLPF) CEO Edward Gudaitis on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 4:17 PM
Trimel: 1Q Earnings SnapshotTrimel: 1Q Earnings Snapshot
finance.yahoo.com - May 15 at 10:39 AM
Acerus Pharmaceuticals Corporation to Host Earnings CallAcerus Pharmaceuticals Corporation to Host Earnings Call
finance.yahoo.com - May 15 at 10:39 AM
Acerus Pharmaceuticals (TRLPF) Set to Announce Quarterly Earnings on TuesdayAcerus Pharmaceuticals (TRLPF) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 9 at 11:23 AM
Trimel Pharmaceuticals (TRLPF) Cut to "Sell" at ValuEngineTrimel Pharmaceuticals (TRLPF) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 6:30 AM
Trimel Pharmaceuticals Corp. (TRLPF) Raised to "Hold" at ValuEngineTrimel Pharmaceuticals Corp. (TRLPF) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - November 28 at 12:36 AM
Trimel reports 3Q lossTrimel reports 3Q loss
finance.yahoo.com - November 7 at 12:21 PM
Trimel Pharmaceuticals Corp. (TRLPF) to Release Earnings on TuesdayTrimel Pharmaceuticals Corp. (TRLPF) to Release Earnings on Tuesday
www.americanbankingnews.com - November 1 at 10:49 AM
Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) to Release Earnings on FridayTrimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) to Release Earnings on Friday
www.americanbankingnews.com - August 5 at 9:06 AM

SEC Filings

Acerus Pharmaceuticals (OTCMKTS:TRLPF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Acerus Pharmaceuticals (OTCMKTS TRLPF) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.